| Full text | |
| Author(s): |
Pasoto, Sandra Gofinet
[1, 2]
;
Natalino, Renato Romera
[2]
;
Chakkour, Henrique Pires
[2]
;
Trindade Viana, Vilma dos Santos
[2]
;
Bueno, Cleonice
[2]
;
Leon, Elaine Pires
[2]
;
Gualhardo Vendramini, Margarete Borges
[2]
;
Levy Neto, Mauricio
[2]
;
Bonfa, Eloisa
[2]
Total Authors: 9
|
| Affiliation: | [1] Univ Sao Paulo, Disciplina Reumatol, Fac Med, BR-01246903 Sao Paulo - Brazil
[2] Univ Sao Paulo, Div Rheumatol, Fac Med, Hosp Clin, BR-01246903 Sao Paulo - Brazil
Total Affiliations: 2
|
| Document type: | Journal article |
| Source: | RHEUMATOLOGY INTERNATIONAL; v. 33, n. 5, p. 1149-1157, MAY 2013. |
| Web of Science Citations: | 17 |
| Abstract | |
Antibody to Epstein-Barr virus (EBV) early antigen diffuse (anti-EA-D) is associated with viral replication. However, their possible associations with clinical/therapeutic features in primary Sjogren's syndrome (pSS) were not established. We evaluated 100 pSS patients (American-European Criteria) and 89 age/gender/ethnicity-matched healthy controls. Disease activity was measured by EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI). Antibodies to EBV (anti-VCA IgG/IgM, anti-EBNA-1 IgG, anti-EA-D IgG) were determined by ELISA. Patients and controls had comparable frequencies and mean levels of anti-VCA IgG (90 vs. 86.5 %, p = 0.501; 2.6 +/- A 1.1 vs. 2.5 +/- A 1.1 AU/mL, p = 0.737) and anti-EBNA-1 IgG (92 vs. 94.4 %, p = 0.576; 141.3 +/- A 69.8 vs. 135.6 +/- A 67.5 RU/mL, p = 0.464). Anti-VCA IgM was negative in all cases. Noteworthy, higher frequency and increased mean levels of anti-EA-D were observed in patients than controls (36 vs. 4.5 %, p < 0.0001; 38.6 +/- A 57.4 vs. 7.9 +/- A 26.3 RU/mL, p < 0.0001). Further analysis of patients with (n = 36) and without (n = 64) anti-EA-D revealed comparable age/gender/ethnicity (p a parts per thousand yen 0.551), current prednisone dose (4.8 +/- A 6.9 vs. 5.1 +/- A 10.4 mg/day, p = 0.319), and current uses of prednisone (52.8 vs. 37.5 %, p = 0.148) and immunosuppressants (44.4 vs. 31.3 %, p = 0.201). ESSDAI values were comparable (p = 0.102), but joint activity was more frequent (25 vs. 9.4 %, p = 0.045) in anti-EA-D positive patients. Anti-EA-D antibodies were not associated with anti-Ro/SSA (p = 1.000), anti-La/SSB (p = 0.652), rheumatoid factor (p = 1.000), anti-alpha-fodrin (p = 0.390) or antiphospholipid antibodies (p = 0.573), not suggesting cross-reactivity. The higher anti-EA-D frequency associated with joint activity raises the possibility that a subclinical EBV reactivation may trigger or perpetuate the articular involvement in pSS. (AU) | |
| FAPESP's process: | 10/10013-4 - Serum autoantibodies in primary Sjögren's syndrome: study of clinical associations and possible correlations with antibodies to viral antigens (EBV and HTLV-1) |
| Grantee: | Sandra Gofinet Pasoto |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 10/13463-0 - Antiphospholipid antibodies in primary Sjogren's syndrome: prevalence and clinical associations |
| Grantee: | Henrique Pires Chakkour |
| Support Opportunities: | Scholarships in Brazil - Scientific Initiation |
| FAPESP's process: | 10/10017-0 - Serum Autoantibodies in Primary Sjögren's Syndrome: Study of Clinical Associations and Possible Correlations with Antibodies to Viral Antigens (EBV and HTLV-1) |
| Grantee: | Renato Romera Natalino |
| Support Opportunities: | Scholarships in Brazil - Scientific Initiation |